Artikel

What are the hidden challenges of living with uncontrolled Atopic Dermatitis (AD) and Prurigo Nodularis (PN)?

As we continue to advance in our understanding and treatment capabilities, our response to uncontrolled AD and PN becomes more effective, paving the way for a future where patients can lead healthier, more comfortable lives⁸.

Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of autoimmune type 1 diabetes (T1D) development.¹ The number of detectable autoantibodies through screening correlates with risk of developing autoimmune T1D.² Assays for detecting autoimmune T1D have shown high sensitivity and specificity.^3,4

Explore the distinct clinical manifestations of Atopic Dermatitis (AD) and Prurigo Nodularis (PN), their impact on patients' lives, and the common thread of type 2 inflammation. Understand how these chronic skin conditions differ and intersect in this comprehensive overview.

The Type 1 Diabetes (T1D) field is evolving.

Recognition of the presymptomatic stages in T1D is growing.^1-4 

The clinical benefits of early detection of T1D are being highlighted.^3-4 Programmes focusing on early detection through testing and screening for presymptomatic autoimmune T1D are increasingly offered to risk populations and the general population.^1,2

Summary of Zoungas S, et al. Diabetologia. 2012;55:636–643.

Practical Guidance based on the 2022 ADA/EASD Guidelines.

Know the signs and symptoms of acquired TTP (aTTP).

Early diagnosis and treatment of Thrombotic thrombocytopenic purpura (TTP) can help prevent the high risk of early deaths.

TTP is rare and presents similarly to other thrombotic microangiopathies (TMAs), making it difficult to diagnose.

Summary of The UK Prospective Diabetes Study (UKPDS).